Reuters logo
BRIEF-Actinium Pharmaceuticals says iomab-b late-stage trial enrollment accelerates
2017年6月15日 / 下午12点41分 / 5 个月前

BRIEF-Actinium Pharmaceuticals says iomab-b late-stage trial enrollment accelerates

June 15 (Reuters) - Actinium Pharmaceuticals Inc-

* Actinium Pharmaceuticals Inc says iomab-b phase 3 sierra trial enrollment is accelerating as number of clinical trial sites increase

* Actinium Pharmaceuticals Inc says actimab-a phase 2 trial remains on target to yield interim data in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below